Thalidomide (CAS 50-35-1)

Thalidomide is a chemical compound extensively studied in various research disciplines, particularly in the field of immunology. It has been used in laboratory settings to investigate its influence on immune system signaling, such as the inhibition of tumor necrosis factor-alpha (TNF-α) production. Researchers have harnessed Thalidomide to explore its modulatory effects on the immune response, including the alteration of cytokine profiles. Moreover, Thalidomide is of interest for its use in research related to angiogenesis. The compound also plays a role in the study of cell proliferation and the expression of adhesion molecules, which are vital for understanding cellular interactions and migration.

References:

1. Angiogenesis-dependent diseases.  |  Folkman, J. 2001. Semin Oncol. 28: 536-42. PMID: 11740806
2. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro.  |  Sampaio, EP., et al. 2002. Biomed Pharmacother. 56: 13-9. PMID: 11905505
3. Long-term remission of Crohn′s disease treated with thalidomide: a seminal case report.  |  Fishman, SJ., et al. 1999. Angiogenesis. 3: 201-4. PMID: 14535285
4. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway.  |  Gockel, HR., et al. 2004. J Immunol. 172: 5103-9. PMID: 15067094
5. Recent advances in analytical determination of thalidomide and its metabolites.  |  Bosch, ME., et al. 2008. J Pharm Biomed Anal. 46: 9-17. PMID: 18023317
6. Palliative oncology: thalidomide.  |  Prommer, EE. 2010. Am J Hosp Palliat Care. 27: 198-204. PMID: 19843880
7. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.  |  Sampaio, EP., et al. 1991. J Exp Med. 173: 699-703. PMID: 1997652
8. Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice.  |  Islas-Espinoza, AM., et al. 2018. J Toxicol Sci. 43: 671-684. PMID: 30405000
9. Thalidomide prevents antibody-mediated immune thrombocytopenia in mice.  |  Xu, M., et al. 2019. Thromb Res. 183: 69-75. PMID: 31670229
10. Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes.  |  Miura, T., et al. 2021. J Toxicol Sci. 46: 311-317. PMID: 34193768
11. Thalidomide Attenuates Skin Lesions and Inflammation in Rosacea-Like Mice Induced by Long-Term Exposure of LL-37.  |  Kang, Y., et al. 2022. Drug Des Devel Ther. 16: 4127-4138. PMID: 36483458
12. Thalidomide is an inhibitor of angiogenesis.  |  D′Amato, RJ., et al. 1994. Proc Natl Acad Sci U S A. 91: 4082-5. PMID: 7513432
13. Thalidomide inhibits the replication of human immunodeficiency virus type 1.  |  Makonkawkeyoon, S., et al. 1993. Proc Natl Acad Sci U S A. 90: 5974-8. PMID: 8327469